32 results
Asthma Medications and Mechanism of Action

#Asthma #Medications #Drugs #Pulmonary #Pharmacology #Management #Treatment
Asthma Medications ... Mechanism of Action #Asthma ... Medications #Drugs #Pulmonary ... #Pharmacology # ... Management #Treatment
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... screen within 1 year ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Recommendations for Preventing ... ) in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Asthma Maintenance Therapy - Stepwise Approach 

Low dose ICS 
-> Low dose ICS/LABA or Med/High dose
Asthma Maintenance ... nonpharmacologic management ... Stepwise #Therapy #Management ... #Pharmacology # ... Pulmonary
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Biologic therapy for eosinophilic asthma 
• Mepolizumab (Nucala) 
  • Anti-lL-5, 100 mg SQ q4
for eosinophilic asthma ... #eosinophilic #asthma ... #Medications #pharmacology ... #pulmonary #management
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... #Treatment #opportunistic ... infections #HIVAIDS #management ... #pharmacology # ... pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology